Published in Biochim Biophys Acta on December 30, 2008
Cancer chemoprevention by dietary polyphenols: promising role for epigenetics. Biochem Pharmacol (2010) 1.63
Epigenetic modifications in cancer. Clin Genet (2011) 1.53
Metastasis suppressor genes at the interface between the environment and tumor cell growth. Int Rev Cell Mol Biol (2011) 1.18
Redefining the impact of nutrition on breast cancer incidence: is epigenetics involved? Nutr Res Rev (2012) 0.93
Epigenetics and cancer. J Appl Physiol (1985) (2010) 0.93
Cancer stem cells: nature versus nurture. Nat Cell Biol (2010) 0.92
Epigenetic deregulation of the anaplastic lymphoma kinase gene modulates mesenchymal characteristics of oral squamous cell carcinomas. Carcinogenesis (2013) 0.84
Ductal barriers in mammary epithelium. Tissue Barriers (2013) 0.80
Presence of glioma stroma mesenchymal stem cells in a murine orthotopic glioma model. Childs Nerv Syst (2011) 0.77
Role of stromal-epithelial interaction in the formation and development of cancer cells. Cancer Microenviron (2013) 0.76
Epigenetic changes in carcinogenesis of gallbladder. Indian J Surg Oncol (2013) 0.75
The fundamental role of epigenetic events in cancer. Nat Rev Genet (2002) 30.05
Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell (2005) 18.20
The history of cancer epigenetics. Nat Rev Cancer (2004) 14.38
The Polycomb group protein EZH2 directly controls DNA methylation. Nature (2005) 13.67
Putting tumours in context. Nat Rev Cancer (2001) 12.37
Epigenetic gene silencing in cancer - a mechanism for early oncogenic pathway addiction? Nat Rev Cancer (2006) 11.22
Reversion of the malignant phenotype of human breast cells in three-dimensional culture and in vivo by integrin blocking antibodies. J Cell Biol (1997) 10.61
TGF-beta signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia. Science (2004) 10.23
Molecular characterization of the tumor microenvironment in breast cancer. Cancer Cell (2004) 9.41
Gene expression signature of fibroblast serum response predicts human cancer progression: similarities between tumors and wounds. PLoS Biol (2004) 9.38
Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium. Cancer Res (1999) 8.63
DNA hypermethylation in tumorigenesis: epigenetics joins genetics. Trends Genet (2000) 6.57
Gene silencing in cancer by histone H3 lysine 27 trimethylation independent of promoter DNA methylation. Nat Genet (2008) 5.08
The organizing principle: microenvironmental influences in the normal and malignant breast. Differentiation (2002) 4.64
An epigenetic road map for histone lysine methylation. J Cell Sci (2003) 4.43
Distinct epigenetic changes in the stromal cells of breast cancers. Nat Genet (2005) 4.33
DNA methylation and histone modifications: teaming up to silence genes. Curr Opin Genet Dev (2005) 4.25
Tenascin: an extracellular matrix protein involved in tissue interactions during fetal development and oncogenesis. Cell (1986) 4.10
Irradiated mammary gland stroma promotes the expression of tumorigenic potential by unirradiated epithelial cells. Cancer Res (2000) 3.95
Frequent somatic mutations in PTEN and TP53 are mutually exclusive in the stroma of breast carcinomas. Nat Genet (2002) 3.89
The stroma as a crucial target in rat mammary gland carcinogenesis. J Cell Sci (2004) 3.83
Context, tissue plasticity, and cancer: are tumor stem cells also regulated by the microenvironment? Cancer Cell (2005) 3.67
Normal human mammary epithelial cells spontaneously escape senescence and acquire genomic changes. Nature (2001) 3.58
The cancer epigenome--components and functional correlates. Genes Dev (2006) 3.40
Transplantation of skin components during chemical carcinogenesis with 20-methylcholanthrene. Br J Cancer (1951) 3.31
Non-steroidal anti-inflammatory drugs for cancer prevention: promise, perils and pharmacogenetics. Nat Rev Cancer (2006) 3.19
Know thy neighbor: stromal cells can contribute oncogenic signals. Curr Opin Genet Dev (2001) 3.12
Cancer as an epigenetic disease: DNA methylation and chromatin alterations in human tumours. J Pathol (2002) 3.00
Cell type-specific DNA methylation patterns in the human breast. Proc Natl Acad Sci U S A (2008) 2.99
Methylation patterns of the E-cadherin 5' CpG island are unstable and reflect the dynamic, heterogeneous loss of E-cadherin expression during metastatic progression. J Biol Chem (2000) 2.97
Senescent human fibroblasts increase the early growth of xenograft tumors via matrix metalloproteinase secretion. Cancer Res (2007) 2.94
Tissue architecture: the ultimate regulator of breast epithelial function. Curr Opin Cell Biol (2003) 2.92
DNA methylation in breast and colorectal cancers. Mod Pathol (2007) 2.88
Stromal cells can contribute oncogenic signals. Semin Cancer Biol (2001) 2.80
Sustained induction of epithelial to mesenchymal transition activates DNA methylation of genes silenced in basal-like breast cancers. Proc Natl Acad Sci U S A (2008) 2.53
Modeling dynamic reciprocity: engineering three-dimensional culture models of breast architecture, function, and neoplastic transformation. Semin Cancer Biol (2005) 2.53
Role of the stromal microenvironment in carcinogenesis of the prostate. Int J Cancer (2003) 2.43
Loss of TGF-beta type II receptor in fibroblasts promotes mammary carcinoma growth and invasion through upregulation of TGF-alpha-, MSP- and HGF-mediated signaling networks. Oncogene (2005) 2.35
Breast stroma plays a dominant regulatory role in breast epithelial growth and differentiation: implications for tumor development and progression. Cancer Res (2001) 2.28
The emerging science of epigenomics. Hum Mol Genet (2006) 2.22
Cancer and aging: a model for the cancer promoting effects of the aging stroma. Int J Biochem Cell Biol (2002) 2.08
CpG islands as genomic footprints of promoters that are associated with replication origins. Curr Biol (1999) 2.02
Breast cancer DNA methylation profiles in cancer cells and tumor stroma: association with HER-2/neu status in primary breast cancer. Cancer Res (2006) 1.99
DNA methylation and complete transcriptional silencing of cancer genes persist after depletion of EZH2. Cancer Res (2007) 1.96
Tumor suppressor p16INK4A regulates polycomb-mediated DNA hypermethylation in human mammary epithelial cells. J Biol Chem (2006) 1.93
The development of a functionally relevant cell culture model of progressive human breast cancer. Semin Cancer Biol (1995) 1.77
The dominance of the microenvironment in breast and ovarian cancer. Semin Cancer Biol (2002) 1.73
Elucidation of a role for stromal steroid hormone receptors in mammary gland growth and development using tissue recombinants. J Mammary Gland Biol Neoplasia (1997) 1.73
Induction of DNA hypomethylation by tumor hypoxia. Epigenetics (2007) 1.45
Effect of stromal and epithelial cells derived from normal and tumorous breast tissue on the proliferation of human breast cancer cell lines in co-culture. Int J Cancer (1997) 1.33
Breast cancer-associated fibroblasts confer AKT1-mediated epigenetic silencing of Cystatin M in epithelial cells. Cancer Res (2008) 1.30
Cellular mechanisms for low-dose ionizing radiation-induced perturbation of the breast tissue microenvironment. Cancer Res (2005) 1.28
The potential influence of radiation-induced microenvironments in neoplastic progression. J Mammary Gland Biol Neoplasia (1998) 1.24
DNA methylation control of tissue polarity and cellular differentiation in the mammary epithelium. Exp Cell Res (2004) 1.23
Epigenetic silencing of the tumor suppressor cystatin M occurs during breast cancer progression. Cancer Res (2006) 1.20
Histone modifying and chromatin remodelling enzymes in cancer and dysplastic syndromes. Hum Mol Genet (2005) 1.18
Concordant epigenetic silencing of transforming growth factor-beta signaling pathway genes occurs early in breast carcinogenesis. Cancer Res (2007) 1.15
Malignant breast epithelium selects for insulin-like growth factor II expression in breast stroma: evidence for paracrine function. Cancer Res (1995) 1.12
Cystatin m: a novel candidate tumor suppressor gene for breast cancer. Cancer Res (2004) 1.10
Aberrant transforming growth factor beta1 signaling and SMAD4 nuclear translocation confer epigenetic repression of ADAM19 in ovarian cancer. Neoplasia (2008) 1.08
Genetic and epigenetic changes in mammary epithelial cells may mimic early events in carcinogenesis. J Mammary Gland Biol Neoplasia (2004) 1.05
Methylation-dependent silencing of CST6 in primary human breast tumors and metastatic lesions. Exp Mol Pathol (2007) 1.01
The insulin-like growth factors, their receptors, and their binding proteins in human breast cancer. Cancer Treat Res (1991) 0.96
Epigenetic reversion of breast carcinoma phenotype is accompanied by changes in DNA sequestration as measured by AluI restriction enzyme. Am J Pathol (2007) 0.94
Hypomethylation and increased gene expression of p16INK4a in primary and metastatic breast carcinoma as compared to normal breast tissue. Oncogene (1998) 0.91
Paracrine/autocrine regulation of breast cancer by the insulin-like growth factors. Breast Cancer Res Treat (1998) 0.91
Loss of chromosomal integrity in human mammary epithelial cells subsequent to escape from senescence. J Mammary Gland Biol Neoplasia (2001) 0.87
Stimulation of urinary bladder tumorigenesis by carcinogen-exposed stroma. J Urol (1990) 0.82
Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Res (2008) 6.38
FOXP3 is an X-linked breast cancer suppressor gene and an important repressor of the HER-2/ErbB2 oncogene. Cell (2007) 3.46
LINE-1 hypomethylation in cancer is highly variable and inversely correlated with microsatellite instability. PLoS One (2007) 2.99
Mapping geographic zones of cancer risk with epigenetic biomarkers in normal breast tissue. Clin Cancer Res (2006) 2.70
Diverse gene expression and DNA methylation profiles correlate with differential adaptation of breast cancer cells to the antiestrogens tamoxifen and fulvestrant. Cancer Res (2006) 2.63
Combinatorial analysis of transcription factor partners reveals recruitment of c-MYC to estrogen receptor-alpha responsive promoters. Mol Cell (2006) 2.48
Analysis of Myc bound loci identified by CpG island arrays shows that Max is essential for Myc-dependent repression. Curr Biol (2003) 2.47
The functional consequences of alternative promoter use in mammalian genomes. Trends Genet (2008) 2.47
T-bet binding to newly identified target gene promoters is cell type-independent but results in variable context-dependent functional effects. J Biol Chem (2006) 2.24
Epigenetic repression of microRNA-129-2 leads to overexpression of SOX4 oncogene in endometrial cancer. Cancer Res (2009) 2.23
Somatic single hits inactivate the X-linked tumor suppressor FOXP3 in the prostate. Cancer Cell (2009) 2.10
High-throughput methylation profiling by MCA coupled to CpG island microarray. Genome Res (2007) 2.09
Epithelial progeny of estrogen-exposed breast progenitor cells display a cancer-like methylome. Cancer Res (2008) 1.99
Loss of estrogen receptor signaling triggers epigenetic silencing of downstream targets in breast cancer. Cancer Res (2004) 1.97
B7DC/PDL2 promotes tumor immunity by a PD-1-independent mechanism. J Exp Med (2003) 1.92
CpG Island microarray probe sequences derived from a physical library are representative of CpG Islands annotated on the human genome. Nucleic Acids Res (2005) 1.89
The Scurfy mutation of FoxP3 in the thymus stroma leads to defective thymopoiesis. J Exp Med (2005) 1.70
STAT3 is necessary for proliferation and survival in colon cancer-initiating cells. Cancer Res (2011) 1.63
EZH2-mediated concordant repression of Wnt antagonists promotes β-catenin-dependent hepatocarcinogenesis. Cancer Res (2011) 1.58
ChIP-chip comes of age for genome-wide functional analysis. Cancer Res (2006) 1.55
Prognostic DNA methylation biomarkers in ovarian cancer. Clin Cancer Res (2006) 1.53
DNA methylation of the Trip10 promoter accelerates mesenchymal stem cell lineage determination. Biochem Biophys Res Commun (2010) 1.52
Identifying estrogen receptor alpha target genes using integrated computational genomics and chromatin immunoprecipitation microarray. Nucleic Acids Res (2004) 1.50
Minireview: epigenetic changes in ovarian cancer. Endocrinology (2009) 1.49
Nanomechanical biomarkers of single circulating tumor cells for detection of castration resistant prostate cancer. Prostate (2014) 1.46
Sequential DNA methylation changes are associated with DNMT3B overexpression in colorectal neoplastic progression. Gut (2010) 1.44
Epigenetic alterations in the breast: Implications for breast cancer detection, prognosis and treatment. Semin Cancer Biol (2009) 1.41
The epigenetics of ovarian cancer drug resistance and resensitization. Am J Obstet Gynecol (2004) 1.41
Antimitogenic and chemosensitizing effects of the methylation inhibitor zebularine in ovarian cancer. Mol Cancer Ther (2005) 1.40
Xenoestrogen-induced epigenetic repression of microRNA-9-3 in breast epithelial cells. Cancer Res (2009) 1.37
High resolution detection and analysis of CpG dinucleotides methylation using MBD-Seq technology. PLoS One (2011) 1.35
Chromatin immunoprecipitation (ChIP) on chip experiments uncover a widespread distribution of NF-Y binding CCAAT sites outside of core promoters. J Biol Chem (2005) 1.30
Breast cancer-associated fibroblasts confer AKT1-mediated epigenetic silencing of Cystatin M in epithelial cells. Cancer Res (2008) 1.30
MPromDb: an integrated resource for annotation and visualization of mammalian gene promoters and ChIP-chip experimental data. Nucleic Acids Res (2006) 1.28
Toward a human epigenome. Nat Genet (2006) 1.28
Methods in DNA methylation profiling. Epigenomics (2009) 1.25
Use of CpG island microarrays to identify colorectal tumors with a high degree of concurrent methylation. Methods (2002) 1.21
Hypermethylation of 18S and 28S ribosomal DNAs predicts progression-free survival in patients with ovarian cancer. Clin Cancer Res (2005) 1.20
Estrogen-mediated epigenetic repression of large chromosomal regions through DNA looping. Genome Res (2010) 1.18
Promoter hypermethylation of FBXO32, a novel TGF-beta/SMAD4 target gene and tumor suppressor, is associated with poor prognosis in human ovarian cancer. Lab Invest (2010) 1.17
Profiling DNA methylomes from microarray to genome-scale sequencing. Technol Cancer Res Treat (2010) 1.17
Differential methylation hybridization: profiling DNA methylation with a high-density CpG island microarray. Methods Mol Biol (2009) 1.15
Targeted methylation of two tumor suppressor genes is sufficient to transform mesenchymal stem cells into cancer stem/initiating cells. Cancer Res (2011) 1.15
Epigenetic repression of the estrogen-regulated Homeobox B13 gene in breast cancer. Carcinogenesis (2008) 1.15
Epigenetic silencing mediated through activated PI3K/AKT signaling in breast cancer. Cancer Res (2011) 1.13
Modulation of genetic and epigenetic biomarkers of colorectal cancer in humans by black raspberries: a phase I pilot study. Clin Cancer Res (2010) 1.12
Genome-wide mapping of RNA Pol-II promoter usage in mouse tissues by ChIP-seq. Nucleic Acids Res (2010) 1.10
Amplification of distant estrogen response elements deregulates target genes associated with tamoxifen resistance in breast cancer. Cancer Cell (2013) 1.09
Aberrant transforming growth factor beta1 signaling and SMAD4 nuclear translocation confer epigenetic repression of ADAM19 in ovarian cancer. Neoplasia (2008) 1.08
Three-tiered role of the pioneer factor GATA2 in promoting androgen-dependent gene expression in prostate cancer. Nucleic Acids Res (2014) 1.05
Identification of miRNAs and their target genes in developing maize ears by combined small RNA and degradome sequencing. BMC Genomics (2014) 1.04
Integrated analysis of genome-wide DNA methylation and gene expression profiles in molecular subtypes of breast cancer. Nucleic Acids Res (2013) 1.03
Inference of hierarchical regulatory network of estrogen-dependent breast cancer through ChIP-based data. BMC Syst Biol (2010) 1.03
Noninvasive imaging of retinal morphology and microvasculature in obese mice using optical coherence tomography and optical microangiography. Invest Ophthalmol Vis Sci (2014) 1.00
Modulation of DNA methylation by a sesquiterpene lactone parthenolide. J Pharmacol Exp Ther (2009) 0.99
Epigenetic influences of low-dose bisphenol A in primary human breast epithelial cells. Toxicol Appl Pharmacol (2010) 0.99
Boosting Wnt activity during colorectal cancer progression through selective hypermethylation of Wnt signaling antagonists. BMC Cancer (2014) 0.98
Methylated DNA immunoprecipitation and microarray-based analysis: detection of DNA methylation in breast cancer cell lines. Methods Mol Biol (2009) 0.96
The androgen receptor gene is preferentially hypermethylated in follicular non-Hodgkin's lymphomas. Clin Cancer Res (2003) 0.95
Hierarchical modularity in ERα transcriptional network is associated with distinct functions and implicates clinical outcomes. Sci Rep (2012) 0.94
A mixture model-based discriminate analysis for identifying ordered transcription factor binding site pairs in gene promoters directly regulated by estrogen receptor-alpha. Bioinformatics (2006) 0.94
Aberrant DNA methylation in ovarian cancer: is there an epigenetic predisposition to drug response? Ann N Y Acad Sci (2003) 0.94
Tilling the chromatin landscape: emerging methods for the discovery and profiling of protein-DNA interactions. Biochem Cell Biol (2005) 0.94
Targeted methylation of CMV and E1A viral promoters. Biochem Biophys Res Commun (2010) 0.94
Epigenetic "bivalently marked" process of cancer stem cell-driven tumorigenesis. Bioessays (2007) 0.94
Estrogen-mediated epigenetic repression of the imprinted gene cyclin-dependent kinase inhibitor 1C in breast cancer cells. Carcinogenesis (2011) 0.93
MicroRNA-21 inhibits p57Kip2 expression in prostate cancer. Mol Cancer (2014) 0.92
Identification of a Cullin5-ElonginB-ElonginC E3 complex in degradation of feline immunodeficiency virus Vif-mediated feline APOBEC3 proteins. J Virol (2011) 0.92
Diverse histone modifications on histone 3 lysine 9 and their relation to DNA methylation in specifying gene silencing. BMC Genomics (2007) 0.92
ChIP-seq defined genome-wide map of TGFβ/SMAD4 targets: implications with clinical outcome of ovarian cancer. PLoS One (2011) 0.92
Aberrant TGFβ/SMAD4 signaling contributes to epigenetic silencing of a putative tumor suppressor, RunX1T1 in ovarian cancer. Epigenetics (2011) 0.92
Black raspberry-derived anthocyanins demethylate tumor suppressor genes through the inhibition of DNMT1 and DNMT3B in colon cancer cells. Nutr Cancer (2013) 0.92
New anti-cancer strategies: epigenetic therapies and biomarkers. Front Biosci (2005) 0.91
Polarity changes in the transmembrane domain core of HIV-1 Vpu inhibits its anti-tetherin activity. PLoS One (2011) 0.91
The role of parental and grandparental epigenetic alterations in familial cancer risk. Cancer Res (2008) 0.90
Quantification of regional DNA methylation by liquid chromatography/tandem mass spectrometry. Anal Biochem (2009) 0.90
Heritable clustering and pathway discovery in breast cancer integrating epigenetic and phenotypic data. BMC Bioinformatics (2007) 0.90
Role of epigenomics in ovarian and endometrial cancers. Epigenomics (2010) 0.89
Computational analysis reveals a correlation of exon-skipping events with splicing, transcription and epigenetic factors. Nucleic Acids Res (2013) 0.89
Self-assembled mPEG-PCL-g-PEI micelles for simultaneous codelivery of chemotherapeutic drugs and DNA: synthesis and characterization in vitro. Int J Nanomedicine (2012) 0.89
Drug-loaded biodegradable microspheres for image-guided combinatory epigenetic therapy in cells. J Biomed Opt (2011) 0.89
Interactions between HIV-1 Vif and human ElonginB-ElonginC are important for CBF-β binding to Vif. Retrovirology (2013) 0.88
Genome-wide analysis uncovers high frequency, strong differential chromosomal interactions and their associated epigenetic patterns in E2-mediated gene regulation. BMC Genomics (2013) 0.87
LOcating non-unique matched tags (LONUT) to improve the detection of the enriched regions for ChIP-seq data. PLoS One (2013) 0.87
Differential DNA methylation of gene promoters in small B-cell lymphomas. Am J Clin Pathol (2005) 0.86
No association between HER-2 gene polymorphism at codon 655 and a risk of bladder cancer. Int J Cancer (2002) 0.85
Identification of candidate epigenetic biomarkers for ovarian cancer detection. Oncol Rep (2009) 0.85
Promoter hypermethylation of CIDEA, HAAO and RXFP3 associated with microsatellite instability in endometrial carcinomas. Gynecol Oncol (2010) 0.85
HRTBLDb: an informative data resource for hormone receptors target binding loci. Nucleic Acids Res (2009) 0.85
Generation of tandem direct duplications by reversed-ends transposition of maize ac elements. PLoS Genet (2013) 0.85
Functional characterization of Trip10 in cancer cell growth and survival. J Biomed Sci (2011) 0.84
Excavating relics of DNA methylation changes during the development of neoplasia. Semin Cancer Biol (2009) 0.84
An application of a service-oriented system to support array annotation in custom chip design for epigenomic analysis. Cancer Inform (2008) 0.84
Enriched transcription factor binding sites in hypermethylated gene promoters in drug resistant cancer cells. Bioinformatics (2008) 0.84
Activation of silenced tumor suppressor genes in prostate cancer cells by a novel energy restriction-mimetic agent. Prostate (2012) 0.84
Epigenetic reprogramming of mesenchymal stem cells. Adv Exp Med Biol (2013) 0.83